Maxim's double upgrade adds to the bullish chorus but comes from a low-accuracy firm against a backdrop of insider selling and deteriorating near-term EPS. Traders should treat this as a mild positive catalyst, focusing on the strong consensus and high short interest for potential squeeze dynamics, but avoid over-weighting the call given the mixed cross-platform signals.
GILD drugs
GILD drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 20 $130.61entry
- T+1 · 6mo ago −0.15%α −0.35% · $130.41
- T+5 · 6mo ago +2.36%α +1.12% · $133.69
- T+20 · 5mo ago −3.95%α −3.91% · $125.45
- T+60 · 3mo ago +5.91%α +1.18% · $138.33
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Maxim Group double-upgraded GILD from Hold to Buy with a $165 price target, implying 26.4% upside from $130.50. The call is contrarian against a backdrop of insider selling and recent EPS estimate cuts, but aligns with an overwhelmingly bullish consensus (31 Buy, 8 Hold, 0 Sell). Maxim’s track record is 43% accurate on 305 calls, well below the average of top-tier firms covering the stock. At $157.57 mean PT, the street sees ~20.7% upside; Maxim’s $165 sits above mean. Over the last 30 days, GILD has seen 1 upgrade and 0 downgrades, but EPS revisions for the current year have been slashed 20 times (0 up). Insider sales totaling ~$3.1M in April–May from C-suite officers (CFO, EVP) diverge bearishly from the upgrade. Short interest stands at a high 55.2% of float, suggesting elevated bearish positioning. Bottom line: the upgrade is a positive trigger, but low analyst accuracy, insider selling, and deteriorating near-term estimates warrant caution despite the bullish consensus.
Impact Score
Consensus & Targets
Consensus is heavily bullish: of 39 analysts, 31 rate Buy (including 11 Strong Buy), 8 Hold, and 0 Sell. This is a strong directional consensus, with no bears. Maxim's upgrade aligns with the majority but comes from a lower-accuracy shop.
Current price $130.50. Mean PT is $157.57, median $160, high $180, low $122. Implied upside to mean is 20.7%. Maxim's $165 is above the mean and median, ranking in the upper quartile. The high PT of $180 from Jefferies (initiated in March) suggests further upside potential if catalysts materialize.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-05-20 | Maxim Group | upgrade | Buy | $165.00 |
| 2026-05-08 | Truist Securities | reiterate | Buy | $157.00 |
| 2026-05-08 | RBC Capital | maintain | Sector Perform | $122.00 |
| 2026-04-13 | Citigroup | maintain | Buy | $165.00 |
| 2026-04-10 | Morgan Stanley | maintain | Overweight | $175.00 |
| 2026-03-10 | Jefferies | initiate | Buy | $180.00 |
| 2026-02-23 | Needham | reiterate | Buy | $170.00 |
| 2026-02-20 | Barclays | initiate | Equal-Weight | $155.00 |
| 2026-02-11 | RBC Capital | maintain | Sector Perform | $118.00 |
| 2026-02-11 | Truist Securities | maintain | Buy | $152.00 |
30-day analyst activity: 1 upgrade (this one), 0 downgrades. EPS revision trend is mixed: current-quarter EPS estimates have 13 downward revisions in 30 days (0 up), and current-year estimates have 20 down (0 up). However, next-quarter and next-year estimates show more balanced revisions (6 up / 0 down and 7 up / 12 down, respectively). The near-term outlook is deteriorating, but forward-looking estimates remain more resilient.
Firm Track Record: Maxim Group
Maxim Group accuracy: 43% on 305 calls | avg return: 5.9%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Truist Securities | 100% | 4/4 | 9.7% | top tier |
| TD Cowen | 100% | 2/2 | 16.2% | top tier |
| Citigroup | 100% | 2/2 | 8.3% | top tier |
| UBS | 100% | 3/3 | 11.5% | top tier |
| Mizuho | 100% | 2/2 | 16.8% | top tier |
| RBC Capital | 93% | 13/14 | 14.9% | top tier |
| Needham | 89% | 8/9 | 12.2% | top tier |
| BMO Capital | 86% | 6/7 | 7.6% | top tier |
| JP Morgan | 86% | 6/7 | 6% | top tier |
| Cantor Fitzgerald | 86% | 6/7 | 17.9% | top tier |
Maxim Group has a 43% accuracy rate on 305 calls with an average return of 5.9%. This is well below top-tier firms like Truist (100% on 4 calls), RBC Capital (93% on 14 calls), and Cantor Fitzgerald (86% on 7 calls returning 17.9%). Best performers: TD Cowen (100%, +16.2% avg), Mizuho (100%, +16.8%). Worst: Maxim itself. The double upgrade carries less weight given this track record.
Earnings Estimates
Next earnings: Aug 5, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $-6.63 | $-7.60 to $-1.31 | $7.4B | ↑0 ↓0 |
| +1q | $1.83 | $-0.89 to $2.57 | $7.8B | ↑6 ↓0 |
| 0y | $-0.81 | $-1.05 to $-0.65 | $30.5B | ↑1 ↓0 |
| +1y | $9.59 | $8.11 to $11.15 | $32.3B | ↑7 ↓0 |
Cross-Platform Signals
Insider trades: Five sells in April–May totaling ~$3.1M from CFO Mercier (two sells) and EVPs Dickinson and O'Day. These sales are consistent with routine vesting/10b5-1 patterns but diverge bearishly from the upgrade. Institutional moves: Norges Bank opened a $2.6B position then exited entirely; Two Sigma initiated; Renaissance trimmed 49%; Ariel trimmed 41%. This mixed institutional activity offers no clear confirmation. Short interest: 55.2% of float, a high level indicating significant bearish positioning that could fuel a squeeze if positive catalysts hit. No congressional trades. Overall, the analyst bullish signal is partially offset by insider selling and institutional churn.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Track record
30 reports on GILD
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +22.38% at T+60 after the Aug 13, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $167.58 Now $167.58 +0.00% settles Feb 16
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $167.71 Now $167.58 −0.08% settles Feb 12
- Nov 13, 20264d ago Court Ruling Bullish 4/10 Entry $170.99 Now $167.58 −1.99% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $168.08 Now $167.58 −0.30% settles Feb 11
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $170.87 Now $167.58 −1.93% settles Feb 8
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $169.32 Now $167.58 −1.03% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 3/10 Entry $167.57 Now $167.58 +0.01% settles Feb 3
- Oct 30, 202617d ago 144 Neutral 3/10 Entry $170.33 Now $167.58 −1.61% settles Jan 29
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $170.68 Now $167.58 −1.82% settles Jan 28
- Oct 22, 202625d ago Institutional Cluster Bearish 4/10 Entry $156.04 Now $167.58 −7.40% settles Jan 21
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers